Bio-Rad Laboratories vs Danaher
Danaher holds the stronger position because its business shows no visible customer loss and sits behind a blocked copy risk, while Bio-Rad is losing chromatography and diagnostics share to Thermo Fisher and to Danaher itself.
Bio-Rad Laboratories
Maker of lab instruments and reagents for gene research and clinical diagnostics testing
Danaher
Makes diagnostic instruments, lab tools, and bioprocessing equipment used across hospitals and biopharma manufacturing
Dimension by dimension
| Dimension | Bio-Rad Laboratories | Danaher |
|---|---|---|
| staying power of the core product | Bio-Rad's process chromatography revenue fell 13% currency-neutral and its diagnostics base is losing share to larger rivals. | Danaher shows no meaningful customer loss in the evidence and is rated hard to displace. |
| exposure to AI | Bio-Rad's lab instruments and reagents are unlikely to be absorbed by AI. | Danaher's diagnostic and bioprocessing equipment are also unlikely to be absorbed by AI. |
| how easily a giant copies them | A larger player could plausibly copy Bio-Rad's offerings. | Danaher's position is rated as blocked from being copied by a giant. |
| pressure from rivals | Bio-Rad faces heavier direct pressure than Danaher, with Thermo Fisher and Danaher actively taking share in diagnostics and chromatography. | Danaher faces lighter direct rival pressure, with no clear rival gains noted. |
| financial footing | Bio-Rad posted FY2025 revenue of $2.58 billion, and Q1 2026 net sales fell 4.2% on a currency-neutral basis. | Danaher posted FY2025 revenue of $24.568 billion and net earnings of $3.614 billion, with a market cap near $144.3 billion. |
| overall competitive strength | Bio-Rad's competitive position is mixed and pressured, weighed down by share losses in chromatography and diagnostics. | Danaher's competitive position is much stronger, supported by broader revenue scale and no visible share losses. |
Questions people ask
- Bio-Rad vs Danaher which is more exposed to AI replacing its products
- Neither Bio-Rad nor Danaher is seen as likely to have its core products absorbed by AI. Both make physical lab and diagnostic instruments that AI does not directly replace.
- Is Bio-Rad losing market share to Danaher
- Yes. Bio-Rad's pressure comes partly from Danaher, along with Thermo Fisher, both of which are winning share in diagnostics and chromatography while Bio-Rad's chromatography revenue fell 13% currency-neutral.
- Which company has stronger finances, Bio-Rad or Danaher
- Danaher is far larger, with FY2025 revenue of $24.568 billion and net earnings of $3.614 billion versus Bio-Rad's FY2025 revenue of $2.58 billion. Danaher also carries a market cap of roughly $144.3 billion.
- Could a bigger company copy Bio-Rad or Danaher's business
- Bio-Rad's offerings are rated as possible to copy by a larger competitor, while Danaher's position is rated as blocked from being copied. This gap favors Danaher's staying power.
Other comparisons with these companies